Received Apr 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Guillian-Barre was a likely result of the immunization; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: Guillian-Barre was a likely result of the immunization) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was resolving. The reporter considered the guillain barre syndrome to be probably related to Shingrix. The company considered the guillain barre syndrome to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 22-MAR-2025 This case was reported by a consumer via interactive digital media. The reporter reported he/she two years into recovering from a Shingrix dose. Because symptoms took a month to develop neither the physician nor himself/herself understood that Guillian Barre was a likely result of the immunization. Therefore, did not get to hospital for as close to a diagnosis as could get. A cautionary tale to encourage people to research this syndrome and be informed enough to seek help. It could had been worse, but it was, and was, a nightmare.; Sender's Comments: Guillain-Barre syndrome is a listed event which, due to the following criteria (insufficient information on medical history, concurrent conditions, concomitant medications, completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingrix.